Aileron Therapeutics
Last update: 10:23AM
Day High/Low0.18 - 0.2
52 Week High/Low0.13 - 0.75
Open / Close0.19 / -
Float / Outstanding71.1M / 90.8M
Vol / Avg.463.8K / 675.3K
Mkt Cap16.8M
50d Avg. Price0.3
Div / Yield-
Payout Ratio-
Total Float71.1M

Aileron Therapeutics (NASDAQ:ALRN), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1


Highest Price Target1


Lowest Price Target1


Consensus Price Target1


Analyst Rating Summary1


Analyst Firms Making Recommendations1

  • HC Wainwright & Co.
  • William Blair

1calculated from analyst ratings published within the last 6 months

Analyst Ratings for Aileron Therapeutics

All Ratings (0)

Upgrades (0)

Downgrades (0)

Initiations (0)

Analyst Firm
Price Target Change
Rating Change
Previous / Current Rating
Get Alert

Aileron Therapeutics Questions & Answers

What is the target price for Aileron Therapeutics (ALRN)?

The latest price target for Aileron Therapeutics (NASDAQ: ALRN) was reported by HC Wainwright & Co. on June 30, 2022. The analyst firm set a price target for $1.00 expecting ALRN to rise to within 12 months (a possible 439.08% upside). 2 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Aileron Therapeutics (ALRN)?

The latest analyst rating for Aileron Therapeutics (NASDAQ: ALRN) was provided by HC Wainwright & Co., and Aileron Therapeutics maintained their buy rating.

When is the next analyst rating going to be posted or updated for Aileron Therapeutics (ALRN)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aileron Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aileron Therapeutics was filed on June 30, 2022 so you should expect the next rating to be made available sometime around June 30, 2023.

Is the Analyst Rating Aileron Therapeutics (ALRN) correct?

While ratings are subjective and will change, the latest Aileron Therapeutics (ALRN) rating was a maintained with a price target of $2.00 to $1.00. The current price Aileron Therapeutics (ALRN) is trading at is $0.19, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.